The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a finite treatment period of 52 weeks in patients with high-risk biochemically relapsed prostate cancer. In ...

The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure. In this video, Sean P. Collins, MD, PhD, a radiation oncologist at Tampa General Hospital in Tampa ...

Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...

Inlexzo provides extended local delivery of gemcitabine, achieving an 82% complete response rate in BCG-unresponsive NMIBC with CIS. The SunRISe-1 trial demonstrated durable responses, with over 50% ...

Detalimogene voraplasmid is a non-viral gene therapy for high-risk NMIBC, aiming to elicit an anti-tumor immune response. The LEGEND trial's pivotal cohort has enrolled 100 patients, with updates ...

AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...